Therapeutic Challenges in Neuroendocrine Tumors

Author(s): Ioannis Legakis*, Muhammad Wasif Saif, Kostantinos Syrigos

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 17 , Issue 7 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Neuroendocrine tumors (NETs) are a diverse set of tumors, being genetically varied. NETs can be presented with a distinct clinical picture, due to the production of various hormones, or being silent. Based on community health clinical statistics, the frequency numbers and reported occurrence of NETs are increasing. Although the therapeutic options for NETs have expanded in recent years, clinical diagnosis is possible only when metastases are present, requiring chronic complicated medical management. A positive development is that the recent evolution of molecularly-targeted therapy in oncology promotes the evolution of innovative tools for the management of these tumors. A diverse assortment of medical specialists is needed to improve outcomes and orchestrate the therapeutic care plan for NET patients.

Keywords: Neuroendocrine tumors, biomarkers, somatostatin analogs, angiogenesis inhibitors, cytotoxic chemotherapy, radionuclide therapy, liver-targeted therapies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 18 June, 2017
Page: [902 - 919]
Pages: 18
DOI: 10.2174/1871520617666170213113401
Price: $65

Article Metrics

PDF: 41